Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.

BACKGROUND & AIMS Irritable bowel syndrome (IBS) has been associated with disruptions to the intestinal microbiota, but studies have had limited power, coverage, and depth of analysis. We aimed to define microbial populations that can be used discriminate the fecal microbiota of patients with IBS from that of healthy subjects and correlate these with IBS intestinal symptom scores. METHODS The microbiota composition was assessed by global and deep molecular analysis of fecal samples from 62 patients with IBS patients and 46 healthy individuals (controls). We used a comprehensive and highly reproducible phylogenetic microarray in combination with quantitative polymerase chain reaction. RESULTS The intestinal microbiota of IBS patients differed significantly (P = .0005) from that of controls. The microbiota of patients, compared with controls, had a 2-fold increased ratio of the Firmicutes to Bacteroidetes (P = .0002). This resulted from an approximately 1.5-fold increase in numbers of Dorea, Ruminococcus, and Clostridium spp (P < .005); a 2-fold decrease in the number of Bacteroidetes (P < .0001); a 1.5-fold decrease in numbers of Bifidobacterium and Faecalibacterium spp (P < .05); and, when present, a 4-fold lower average number of methanogens (3.50 × 10(7) vs 8.74 × 10(6) cells/g feces; P = .003). Correlation analysis of the microbial groups and IBS symptom scores indicated the involvement of several groups of Firmicutes and Proteobacteria in the pathogenesis of IBS. CONCLUSIONS Global and deep molecular analysis of fecal samples indicates that patients with IBS have a different composition of microbiota. This information might be used to develop better diagnostics and ultimately treatments for IBS.

[1]  P. Lawson,et al.  Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia hydrogenotrophica comb. nov., Blautia luti comb. nov , 2008, International journal of systematic and evolutionary microbiology.

[2]  S. Fukudo,et al.  Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[3]  Willem M. de Vos,et al.  The Host Genotype Affects the Bacterial Community in the Human Gastrointestinal Tract , 2001 .

[4]  Hauke Smidt,et al.  Diversity of the human gastrointestinal tract microbiota revisited. , 2007, Environmental microbiology.

[5]  J. Doré,et al.  Low counts of Faecalibacterium prausnitzii in colitis microbiota , 2009, Inflammatory bowel diseases.

[6]  S. Collins,et al.  The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. , 2009, Gastroenterology.

[7]  W. D. de Vos,et al.  Comparative Analysis of Pyrosequencing and a Phylogenetic Microarray for Exploring Microbial Community Structures in the Human Distal Intestine , 2009, PloS one.

[8]  K. Garsed,et al.  Postinfectious irritable bowel syndrome. , 2009, Gastroenterology.

[9]  M. Vatn,et al.  Irritable bowel syndrome in twins: genes and environment , 2006, Gut.

[10]  Jan Lepš,et al.  Multivariate Analysis of Ecological Data using CANOCO , 2003 .

[11]  D. Santini,et al.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.

[12]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[13]  E. Zoetendal,et al.  Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota , 2007, Alimentary pharmacology & therapeutics.

[14]  R. Spiller.  Inflammation as a basis for functional GI disorders. , 2004, Best practice & research. Clinical gastroenterology.

[15]  Peer Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[16]  J. Nikkilä,et al.  Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. , 2010, World journal of gastroenterology.

[17]  P. Scully,et al.  Plasma Cytokine Profiles in Females With Irritable Bowel Syndrome and Extra-Intestinal Co-Morbidity , 2010, The American Journal of Gastroenterology.

[18]  R. Spiller,et al.  Postinfectious irritable bowel syndrome. , 2003, Gastroenterology.

[19]  W. D. de Vos,et al.  Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults , 2009, Environmental microbiology.

[20]  R. Spiller.  Review article: probiotics and prebiotics in irritable bowel syndrome , 2008, Alimentary pharmacology & therapeutics.

[21]  J. Sanderson,et al.  Treating irritable bowel syndrome with probiotics: the evidence , 2010, Proceedings of the Nutrition Society.

[22]  P. Brigidi,et al.  Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians , 2010, PloS one.

[23]  R. Kekkonen,et al.  Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. , 2008, World journal of gastroenterology.

[24]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[25]  K W Heaton,et al.  Functional bowel disorders and functional abdominal pain , 1999, Gut.

[26]  R. Spiller,et al.  Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes , 2006, The American Journal of Gastroenterology.

[27]  M. Affolter,et al.  A Serpin from the Gut Bacterium Bifidobacterium longum Inhibits Eukaryotic Elastase-like Serine Proteases* , 2006, Journal of Biological Chemistry.

[28]  W. D. de Vos,et al.  Do nutrient–gut–microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[29]  G. Boeckxstaens,et al.  The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome , 2010, Gut.

[30]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[31]  D. Katzka.  The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects , 2008 .

[32]  Michiel Kleerebezem,et al.  High temporal and inter-individual variation detected in the human ileal microbiota. , 2010, Environmental microbiology.

[33]  S. Rana,et al.  Incidence of Predominant Methanogenic Flora in Irritable Bowel Syndrome Patients and Apparently Healthy Controls from North India , 2008, Digestive Diseases and Sciences.

[34]  J. Nikkilä,et al.  Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes , 2010, BMC gastroenterology.

[35]  E. Zoetendal,et al.  High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota , 2008, Gut.

[36]  Jones Va,et al.  Some aspects of colonic microbial activity in irritable bowel syndrome associated with food intolerance. , 1986 .

[37]  R. Langer,et al.  Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. , 2009, Gastroenterology.

[38]  G. Macfarlane,et al.  Studies on Amine Production in the Human Colon: Enumeration of Amine forming Bacteria and Physiological Effects of Carbohydrate and pH , 1996 .

[39]  G. Macfarlane,et al.  Contribution of the microflora to proteolysis in the human large intestine. , 1988, The Journal of applied bacteriology.

[40]  M. Thabane,et al.  Post-infectious irritable bowel syndrome. , 2009, World journal of gastroenterology.

[41]  A. Palva,et al.  Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR , 2005, The American Journal of Gastroenterology.

[42]  Anne Salonen,et al.  Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. , 2010, Microbiology.

[43]  H. Lochs,et al.  Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease , 2005, Journal of Clinical Microbiology.

[44]  David Thompson,et al.  Functional bowel disorders , 2005, Digestive Diseases and Sciences.

[45]  M. Samsom,et al.  Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. , 2009, World journal of gastroenterology.

[46]  M. Elia,et al.  Abnormal colonic fermentation in irritable bowel syndrome , 1998, The Lancet.

[47]  Marcus J. Claesson,et al.  Genome-scale analyses of health-promoting bacteria: probiogenomics , 2009, Nature Reviews Microbiology.